Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

The study began on April 11, 2021, and was last updated on August 4, 2025. However, it has been terminated, which could impact the timeline for any potential market release of SAR444881.

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Paris Thursday, August 7, 2025, 10:00 Hrs [IST] Sanofi announces the completion of its acquisition of Vigil Neuroscience, I ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Sanofi SA ( (SNY) ), Sanofi ( (SNYNF) ), Sanofi ( (DE:SNW)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...